Published in Ther Drug Monit on January 01, 1983
Monitoring in chronic disease: a rational approach. BMJ (2005) 2.20
Use and misuse of a digoxin assay service. Br Med J (Clin Res Ed) (1986) 0.99
Quality of requests for serum digoxin concentrations: experience from an Australian regional health service. Br J Clin Pharmacol (2006) 0.86
Recommendations from the Canadian Hypertension Society Consensus Conference on the Pharmacologic Treatment of Hypertension. CMAJ (1989) 4.76
Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther (1976) 3.16
Xylazine hydrochloridine (Rompun) overdose in man. Clin Toxicol (1979) 2.00
Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate. Clin Pharmacol Ther (1974) 1.81
Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther (1977) 1.77
Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol (1976) 1.71
Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol (1984) 1.66
Plasma digoxin concentrations in patients on admission to hospital. Br Heart J (1974) 1.46
Simplified liquid-chromotographic analysis for cyclosporin A, and comparison with radioimmunoassay. Clin Chem (1983) 1.38
Duration of action of beta-blocking drugs. Br Med J (1973) 1.33
Variability in prescription drug utilization: issues for research. CMAJ (1996) 1.24
Quinidine-rifampin interaction. N Engl J Med (1981) 1.14
Measurement of partial agonist activity of pindolol. Clin Pharmacol Ther (1981) 1.13
Correlation of reduction of exercise heart rate with blood levels of atenolol after oral and intravenous administration. Postgrad Med J (1977) 1.13
Phenytoin-theophylline interaction. N Engl J Med (1982) 1.10
Systemic toxicity of para-phenylenediamine. Lancet (1983) 1.08
Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology (1988) 1.08
Cardiac dose-response relationships of oral and intravenous pindolol. Br J Clin Pharmacol (1982) 1.08
Relationships between heart rate and PR interval during physiological and pharmacological interventions. Br J Clin Pharmacol (1987) 1.03
Grapefruit juice--felodipine interaction in the elderly. Clin Pharmacol Ther (2000) 1.01
Severe coughing during captopril and enalapril therapy. CMAJ (1986) 1.01
Evaluation and application of the linear variable differential transformer technique for the assessment of human dorsal hand vein alpha-receptor activity. Clin Pharmacol Ther (1985) 1.00
Correlation between plasma diphenhydramine level and sedative and antihistamine effects. Clin Pharmacol Ther (1978) 0.99
Effect of posture on lung volume: airway closure and gas exchange in hemidiaphragmatic paralysis. Thorax (1979) 0.97
Tolerance and cardiovascular effects of single dose felodipine/beta-blocker combinations in healthy subjects. J Cardiovasc Pharmacol (1987) 0.97
A study of efficacy, tolerance and compliance of once-daily versus twice-daily metoprolol (Betaloc) in hypertension. Betaloc Compliance Canadian Cooperative Study Group. Clin Invest Med (1984) 0.97
Impaired enzyme induction by rifampicin in the elderly. Br J Clin Pharmacol (1984) 0.95
A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke (1985) 0.93
Increased venous alpha-adrenoceptor responsiveness in patients with reflex sympathetic dystrophy. Ann Intern Med (1993) 0.93
Cyclosporin-erythromycin interaction in normal subjects. Br J Clin Pharmacol (1987) 0.92
Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation (1982) 0.91
Respiratory and cardiac effects of metoprolol and bevantolol in patients with asthma. Clin Pharmacol Ther (1986) 0.91
Mean apical concentration and duration in the comparative bioavailability of slowly absorbed and eliminated drug preparations. J Pharm Sci (1988) 0.89
The influence of age on dorsal hand vein responsiveness to norepinephrine. Clin Pharmacol Ther (1986) 0.87
Septic arthritis due to Nocardia asteroides in association with pulmonary alveolar proteinosis. J Rheumatol (1982) 0.86
Digoxin therapy during T-tube biliary drainage in man. JAMA (1978) 0.86
Relation of amiodarone hepatic and pulmonary toxicity to serum drug concentrations and superoxide dismutase activity. Am J Cardiol (1990) 0.86
Simplified liquid-chromatographic assay of amiodarone and desethylamiodarone after solid-phase extraction. Clin Chem (1986) 0.86
Creatinine elevation in patients receiving amiodarone correlates with serum amiodarone concentration. Br J Clin Pharmacol (1993) 0.85
Pulmonary interstitial fibrosis associated with alveolar proteinosis. Thorax (1983) 0.83
Correlation of amiodarone dosage, heart rate, QT interval and corneal microdeposits with serum amiodarone and desethylamiodarone concentrations. Am J Cardiol (1989) 0.83
Cholestyramine and spironolactone and their combination in digitoxin elimination. Clin Pharmacol Ther (1980) 0.82
The effect of exercise on the deposition of an inhaled aerosol. Respir Physiol (1984) 0.82
Genetic aspects of variability in superficial vein responsiveness to norepinephrine. Clin Pharmacol Ther (1991) 0.82
Familial studies of heritability of alpha1-adrenergic receptor responsiveness in superficial veins. Clin Pharmacol Ther (1997) 0.82
Ineffectiveness of beta-adrenergic blockers on ventilatory response to carbon dioxide. Clin Pharmacol Ther (1982) 0.81
Ectopic right upper lobe bronchus as a cause of breathlessness. Thorax (1987) 0.81
Studies on the postnatal development of the collecting ducts of the rat kidney, with particular reference to their glycogen content. Acta Anat (Basel) (1974) 0.80
Acute pancreatitis and Cushing's syndrome. Postgrad Med J (1984) 0.80
Pulmonary infection with opportunist mycobacteria on Merseyside 1974-1983. Postgrad Med J (1986) 0.79
On paradigms, paradoxes, and particles. Lung (1983) 0.78
Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study. Hypertension (1994) 0.77
A double-blind, randomized trial of PY108-068 in acute ischemic cerebral infarction. Stroke (1989) 0.77
Plasma and tissue digoxin concentrations in patients undergoing cardiopulmonary bypass. Br Heart J (1975) 0.76
Influence of cardioselectivity and respiratory disease on pulmonary responsiveness to beta-blockade. Eur J Clin Pharmacol (1984) 0.76
Quinidine interaction with nifedipine and felodipine: pharmacokinetic and pharmacodynamic evaluation. Clin Pharmacol Ther (1993) 0.76
Contrasts between pindolol and propranolol concentration-response relationships. Br J Clin Pharmacol (1985) 0.75
The heart rate-PR interval relationship: a model for evaluating drug actions on SA and AV nodal function. Br J Clin Pharmacol (1990) 0.75
Persistent tardive dyskinesia. Br Med J (1971) 0.75
The cyclosporin-erythromycin interaction: impaired first pass metabolism in the pig. Br J Pharmacol (1991) 0.75
Rebound elevation of cortisol following cyproheptadine withdrawal in Cushing's disease from a pituitary macroadenoma. J Endocrinol Invest (1987) 0.75
Elevation of serum total cholesterol and triglyceride levels during amiodarone therapy. Am J Cardiol (1988) 0.75
Eczema. J Natl Med Assoc (1910) 0.75
Observations on three dosage forms of pindolol. Am Heart J (1982) 0.75
Gastric emptying before and after transverse gastroplasty for morbid obesity. Clin Nucl Med (1986) 0.75
Lung imaging in alpha-1-antitrypsin deficiency. J Can Assoc Radiol (1981) 0.75
Verapamil in chronic atrial fibrillation: variable patterns of response in ventricular rate. Clin Cardiol (1984) 0.75
Coexisting medical problems: assessment and management for surgery. Int Anesthesiol Clin (1984) 0.75
After Eastman: a boost for clinical research? Clin Invest Med (1986) 0.75
Measurement of partial agonist activity in man and its therapeutic relevance. Arq Bras Cardiol (1984) 0.75
Interaction between oral verapamil and beta-blockers during submaximal exercise: relevance of ancillary properties. Clin Pharmacol Ther (1991) 0.75
Kinetics of pamatolol, a cardioselective beta adrenoreceptor blocker. Clin Pharmacol Ther (1979) 0.75
Evaluation of once daily endralazine in hypertension. Eur J Clin Pharmacol (1986) 0.75
Comparison of the electrophysiologic effects of intravenous and oral verapamil in patients with paroxysmal supraventricular tachycardia. Am J Cardiol (1982) 0.75
Accelerated systemic hypertension after cardiac transplantation--possible vascular alpha-receptor hypersensitivity. Am J Cardiol (1984) 0.75
Biliary excretion and enterohepatic recirculation of practolol in man. Ir J Med Sci (1976) 0.75
Pamatolol: phase I evaluation of the pharmacodynamics of a cardioselective beta adrenoceptor blocking drug. Clin Pharmacol Ther (1978) 0.75
Duration of drug action. Am Fam Physician (1980) 0.75